"FDA Approves Eli Lilly's Potent Obesity Drug, Zepbound, for Weight Loss"
TL;DR Summary
The FDA has approved Eli Lilly's drug tirzepatide, marketed as Mounjaro for type 2 diabetes, for the treatment of obesity under the name Zepbound. Zepbound targets both the GLP-1 and GIP hormones and has shown up to 21% weight loss in trials. The approval introduces competition for Novo Nordisk's obesity treatment Wegovy, which has faced shortages. Both drugs have common side effects such as nausea and diarrhea. Lilly plans to double its manufacturing capacity to meet demand and will sell Zepbound at a list price of $1,059.87 per month. The drug is expected to be available in American pharmacies after Thanksgiving.
- FDA approves potent Eli Lilly obesity drug, Zepbound - STAT STAT
- FDA approves new weight loss drug Zepbound NBC News
- FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity under new name, Zepbound CNN
- FDA approves Eli Lilly's Mounjaro for weight loss Yahoo Finance
- Diabetes drug authorised for weight management and loss – MHRA Yahoo News UK
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
4 min
vs 5 min read
Condensed
90%
995 → 101 words
Want the full story? Read the original article
Read on STAT